Heparin Market
Heparin Market Forecasts to 2028 - Global Analysis By Source (Bovine, Porcine and Other Sources), Global Heparin Market, By Administration Route (Subcutaneous, Intravenous and Other Administration Routes), Dosage Form, Ingredient, Therapeutics, Product, Application, Distribution Channel, End User and By Geography
|
Years Covered |
2020-2028 |
|
Estimated Year Value (2022) |
US $7.4 BN |
|
Projected Year Value (2028) |
US $8.6 BN |
|
CAGR (2022 - 2028) |
2.4% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Heparin Market is accounted for $7.4 billion in 2022 and is expected to reach $8.6 billion by 2028 growing at a CAGR of 2.4% during the forecast period. Heparin is considered as one of the most essential drug for preserving life. It is a member of the anticoagulant medication family. Heparin is used as therapy for several chronic diseases. The drug possesses potent anti-inflammatory properties. It is injected into a vein or injected under the skin. It manages cardiac, orthopedic, deep vein thrombosis, pulmonary embolism, and renal disorders. Its use also extends to the administration of major orthopedic procedures such as hip and knee replacements. It prevents blood clotting in patients with specific medical conditions or who are undergoing medical procedures such as open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions.
According to CDC in 2022, 659,000 people in the United States die from heart disease each year which is 1 in every 4 deaths and was marked as one of the major causes of death in the country.
Market Dynamics:
Driver:
Growing prevalence of chronic diseases and surgeries
The increasing number of patients having orthopedic, deep vein thrombosis, pulmonary embolism, renal diseases and cardiac operations, as well as the use of heparin in these surgeries raised the usage of heparin. It helps to keep the blood from clotting and prevents excessive coagulation during operations and supports several off-label uses. Heparin mostly helps certain patients, especially those who must have certain types of surgery or who must remain in bed for a long time. These factors are fuelling the market demand.
Restraint:
Adverse side-effects
Heparin misuse or improper dosage can result in joint pain, stiffness, backaches, bleeding, spitting up blood, oozing from wounds and abdominal pain. Negative effects take a while to recover from. They irritate and cause severe discomfort. These side effects frequently make treatment more difficult and raise the total cost of therapy. These factors are hindering the growth of the market.
Opportunity:
Rising government support
Government funds have been raised for heparin research and development that will create it with better therapeutic potential and fewer side effects. Heparin greatly enhances pain relief, promotes quicker recovery, reduces complications, and shortens hospital stays. So, the government combined the lack of familial support with the provision of free care at a government-funded hospital. These aspects are propelling the market expansion.
Threat:
High medical costs & stringent regulations
The price of heparin therapy is relatively high. It requires regular monthly follow ups. Frequent treatments are making it the most costly medication. Government imposed rigorous controls since the heavy dosage of drug causes numerous negative side effects. The market's expansion is being hampered by its increasingly frequent use and negative consequences.
Covid-19 Impact
The COVID-19 epidemic has greatly increased market demand. COVID patients frequently develop aberrant blood clots because of clot-promoting auto antibodies that cause pulmonary embolisms and deep vein thrombosis, which presents a heparin opportunity. Early anticoagulation treatment with low-molecular-weight heparin effectively prevents COVID associated coagulopathy and endotheliopathy, which improve patient prognosis. These factors raised the demand for the market during pandemic.
The outpatient segment is expected to be the largest during the forecast period
The outpatient segment is estimated to have a lucrative growth, due to its high convenience and services. Due to the decrease in hospital expenditures, including those associated with hospital admission and other forms of hospitality, outpatients have an advantage over other patients. The significant proportion of this market is mostly due to low prices, expanded service availability, and patient comfort.
The intravenous segment is expected to have the highest CAGR during the forecast period
The intravenous segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its easy accessibility. The intravenous method is used to give heparin, particularly unfractionated heparin. It allows quick bloodstream entrance and works quickly to avoid blood clots. The intravenous form of administration also makes it simpler to manage drug concentration in the blood.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to the increase in cardiovascular diseases and accidents. Other variables that contribute to the region's high proportion include rising healthcare spending and rising patient awareness in this area. This region faces high annual deaths i.e. every 1 in 4 fatalities. These elements are raising the demand for heparin in this region.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rising geriatric population. Moreover, Asia Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic versions of medications whose patents have expired are produced locally at a reasonable price. Large chronically ill population and expanding economy are two of the main drivers of the market growth in this region.
Key players in the market
Some of the key players profiled in the Heparin Market include LEO Pharma A/S, Dr. Reddy’s Laboratories Ltd, Aspen Holdings, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceuticals, Fresenius SE & Co, Sanofi, Viatris Inc, Baxter International Inc, Pfizer Inc, United Biotech Ltd, Syntex SA, B. Braun Medical Inc, Leap Labchem Co, Bristol-Myers Squibb Co and Anselm Pharmaceuticals.
Key Developments:
In April 2022, Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.
In April 2022, Dr.Reddy's Laboratories Ltd. along with its subsidiaries together and MediCane Health Inc. with its subsidiaries together announced the launch of its medical cannabis product in Germany. As part of collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.
In March 2021, Teva announced the launch of the first generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%. This is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. This works by decreasing the amount of fluid in the eye. The product was developed by Indoco Remedies and will be manufactured at its facility in Goa, India.
Sources Covered:
• Bovine
• Porcine
• Other Sources
Administration Routes Covered:
• Subcutaneous
• Intravenous
• Other Administration Routes
Dosage Forms Covered:
• Solution
• Injection
• Other Dosage Forms
Ingredients Covered:
• Sodium
• Calcium
• Other Ingredients
Therapeutics Covered:
• Respiratory
• Cardiovascular
• Nephrology
• Oncology
• Central Nervous System
• Other Therapeutics
Products Covered:
• Unfractionated Heparin
• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Other Products
Applications Covered:
• Deep Vein Thrombosis
• Coronery Artery Disease
• Pulmonary Embolism
• Atrial Fibrillation
• Venous Thromboembolism
• Renal Impairment
• Heart Attack
• Other Applications
Distribution Channels Covered:
• Hospitals
• Drug Stores
• Online Pharmacies
• Retail Pharmacies
End Users Covered:
• Inpatient
• Outpatient
• Homecare
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Heparin Market, By Source
5.1 Introduction
5.2 Bovine
5.3 Porcine
5.4 Other Sources
6 Global Heparin Market, By Administration Route
6.1 Introduction
6.2 Subcutaneous
6.3 Intravenous
6.4 Other Administration Routes
7 Global Heparin Market, By Dosage Form
7.1 Introduction
7.2 Solution
7.3 Injection
7.4 Other Dosage Forms
8 Global Heparin Market, By Ingredient
8.1 Introduction
8.2 Sodium
8.3 Calcium
8.5 Other Ingredients
9 Global Heparin Market, By Therapeutics
9.1 Introduction
9.2 Respiratory
9.3 Cardiovascular
9.4 Nephrology
9.5 Oncology
9.6 Central Nervous System
9.7 Other Therapeutics
10 Global Heparin Market, By Product
10.1 Introduction
10.2 Unfractionated Heparin
10.3 Low Molecular Weight Heparin
10.4 Ultra-low Molecular Weight Heparin
10.5 Other Products
11 Global Heparin Market, By Application
11.1 Introduction
11.2 Deep Vein Thrombosis
11.3 Coronery Artery Disease
11.4 Pulmonary Embolism
11.5 Atrial Fibrillation
11.6 Venous Thromboembolism
11.7 Renal Impairment
11.8 Heart Attack
11.9 Other Applications
12 Global Heparin Market, By Distribution Channel
12.1 Introduction
12.2 Hospitals
12.3 Drug Stores
12.4 Online Pharmacies
12.5 Retail Pharmacies
13 Global Heparin Market, By End User
13.1 Introduction
13.2 Inpatient
13.3 Outpatient
13.4 Homecare
13.5 Other End Users
14 Global Heparin Market, By Geography
14.1 Introduction
14.2 North America
14.2.1 US
14.2.2 Canada
14.2.3 Mexico
14.3 Europe
14.3.1 Germany
14.3.2 UK
14.3.3 Italy
14.3.4 France
14.3.5 Spain
14.3.6 Rest of Europe
14.4 Asia Pacific
14.4.1 Japan
14.4.2 China
14.4.3 India
14.4.4 Australia
14.4.5 New Zealand
14.4.6 South Korea
14.4.7 Rest of Asia Pacific
14.5 South America
14.5.1 Argentina
14.5.2 Brazil
14.5.3 Chile
14.5.4 Rest of South America
14.6 Middle East & Africa
14.6.1 Saudi Arabia
14.6.2 UAE
14.6.3 Qatar
14.6.4 South Africa
14.6.5 Rest of Middle East & Africa
15 Key Developments
15.1 Agreements, Partnerships, Collaborations and Joint Ventures
15.2 Acquisitions & Mergers
15.3 New Product Launch
15.4 Expansions
15.5 Other Key Strategies
16 Company Profiling
16.1 LEO Pharma A/S
16.2 Dr. Reddy’s Laboratories Ltd
16.3 Aspen Holdings
16.4 Novartis AG
16.5 GlaxoSmithKline plc
16.6 Teva Pharmaceuticals
16.7 Fresenius SE & Co
16.8 Sanofi
16.9 Viatris Inc
16.10 Baxter International Inc
16.11 Pfizer Inc
16.12 United Biotech Ltd
16.13 Syntex SA
16.14 B. Braun Medical Inc
16.15 Leap Labchem Co
16.16 Bristol-Myers Squibb Co
16.17 Anselm Pharmaceuticals
List of Tables
1 Global Heparin Market Outlook, By Region (2020-2028) ($MN)
2 Global Heparin Market Outlook, By Source (2020-2028) ($MN)
3 Global Heparin Market Outlook, By Bovine (2020-2028) ($MN)
4 Global Heparin Market Outlook, By Porcine (2020-2028) ($MN)
5 Global Heparin Market Outlook, By Other Sources (2020-2028) ($MN)
6 Global Heparin Market Outlook, By Administration Route (2020-2028) ($MN)
7 Global Heparin Market Outlook, By Subcutaneous (2020-2028) ($MN)
8 Global Heparin Market Outlook, By Intravenous (2020-2028) ($MN)
9 Global Heparin Market Outlook, By Other Administration Routes (2020-2028) ($MN)
10 Global Heparin Market Outlook, By Dosage Form (2020-2028) ($MN)
11 Global Heparin Market Outlook, By Solution (2020-2028) ($MN)
12 Global Heparin Market Outlook, By Injection (2020-2028) ($MN)
13 Global Heparin Market Outlook, By Other Dosage Forms (2020-2028) ($MN)
14 Global Heparin Market Outlook, By Ingredient (2020-2028) ($MN)
15 Global Heparin Market Outlook, By Sodium (2020-2028) ($MN)
16 Global Heparin Market Outlook, By Calcium (2020-2028) ($MN)
17 Global Heparin Market Outlook, By Other Ingredients (2020-2028) ($MN)
18 Global Heparin Market Outlook, By Therapeutics (2020-2028) ($MN)
19 Global Heparin Market Outlook, By Respiratory (2020-2028) ($MN)
20 Global Heparin Market Outlook, By Cardiovascular (2020-2028) ($MN)
21 Global Heparin Market Outlook, By Nephrology (2020-2028) ($MN)
22 Global Heparin Market Outlook, By Oncology (2020-2028) ($MN)
23 Global Heparin Market Outlook, By Central Nervous System (2020-2028) ($MN)
24 Global Heparin Market Outlook, By Other Therapeutics (2020-2028) ($MN)
25 Global Heparin Market Outlook, By Product (2020-2028) ($MN)
26 Global Heparin Market Outlook, By Unfractionated Heparin (2020-2028) ($MN)
27 Global Heparin Market Outlook, By Low Molecular Weight Heparin (2020-2028) ($MN)
28 Global Heparin Market Outlook, By Ultra-low Molecular Weight Heparin (2020-2028) ($MN)
29 Global Heparin Market Outlook, By Other Products (2020-2028) ($MN)
30 Global Heparin Market Outlook, By Application (2020-2028) ($MN)
31 Global Heparin Market Outlook, By Deep Vein Thrombosis (2020-2028) ($MN)
32 Global Heparin Market Outlook, By Coronery Artery Disease (2020-2028) ($MN)
33 Global Heparin Market Outlook, By Pulmonary Embolism (2020-2028) ($MN)
34 Global Heparin Market Outlook, By Atrial Fibrillation (2020-2028) ($MN)
35 Global Heparin Market Outlook, By Venous Thromboembolism (2020-2028) ($MN)
36 Global Heparin Market Outlook, By Renal Impairment (2020-2028) ($MN)
37 Global Heparin Market Outlook, By Heart Attack (2020-2028) ($MN)
38 Global Heparin Market Outlook, By Other Applications (2020-2028) ($MN)
39 Global Heparin Market Outlook, By Distribution Channel (2020-2028) ($MN)
40 Global Heparin Market Outlook, By Hospitals (2020-2028) ($MN)
41 Global Heparin Market Outlook, By Drug Stores (2020-2028) ($MN)
42 Global Heparin Market Outlook, By Online Pharmacies (2020-2028) ($MN)
43 Global Heparin Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
44 Global Heparin Market Outlook, By End User (2020-2028) ($MN)
45 Global Heparin Market Outlook, By Inpatient (2020-2028) ($MN)
46 Global Heparin Market Outlook, By Outpatient (2020-2028) ($MN)
47 Global Heparin Market Outlook, By Homecare (2020-2028) ($MN)
48 Global Heparin Market Outlook, By Other End Users (2020-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
